Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04915508 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

Study acronym: EXCALIBUR
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruitingv8 Show 4 more changesShow less
    • Enrollment target: estimated 102 to confirmed 165
    • Primary completion date: Aug 1, 2026 to Dec 31, 2026
    • Study completion date: Aug 1, 2027 to Dec 31, 2027
    • Site details revised
  2. Site contact updatedv7
  3. 3 versions Re-verified since Jul 1, 2022, no change to tracked fieldsv4-v6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2021 to Jun 23, 2021
    • Site details revised
    v3
  5. Primary endpoints revised (2)
    • Secondary endpoints: details revised at 2 of 7 entries
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
Trial Details
NCT Number NCT04915508
Lead Sponsor Jonsson Comprehensive Cancer Center
Conditions
(from sponsor)		 Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Related terms Prostatic Neoplasms
Enrollment 165 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov